Skip to main content
Clinical Trials/NCT05545735
NCT05545735
Terminated
Phase 4

Duration of Antibiotic Therapy for Early (DATE) Ventilator-Associated Pneumonia (VAP) Trial: A Surgical Infection Society Multicenter Randomized Clinical Trial of 4 vs. 7 Days of Definitive Antibiotic Therapy for Early VAP

University of Miami1 site in 1 country27 target enrollmentMay 8, 2023

Overview

Phase
Phase 4
Intervention
Standard of Care Antibiotic Therapy
Conditions
Ventilator Associated Pneumonia
Sponsor
University of Miami
Enrollment
27
Locations
1
Primary Endpoint
Antibiotic Free Days
Status
Terminated
Last Updated
3 months ago

Overview

Brief Summary

The purpose of this study is to see if the amount of antibiotics given for ventilator-associated pneumonia (VAP) can be decreased in order to reduce the risk of adverse effects associated with antibiotics, while at the same time ensuring the participant's safety.

Registry
clinicaltrials.gov
Start Date
May 8, 2023
End Date
February 27, 2025
Last Updated
3 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jonathan Meizoso

Assistant Professor of Surgery

University of Miami

Eligibility Criteria

Inclusion Criteria

  • Surgical patient
  • Early VAP, defined as VAP occurring within 2 - 7 days of intubation (via endotracheal or tracheostomy tube) (9). VAP will be defined according to local institutional protocol.
  • Hospital length of stay (LOS) \< 10 days at the time of VAP diagnosis.
  • Patients are willing to provide informed consent or their Legally Authorized Representative (LAR) is willing to provide informed consent on their behalf when the patient is unable (i.e., cognitively impaired from sedation on a ventilator)

Exclusion Criteria

  • Age \< 18 years
  • Prior episode of VAP for the index admission
  • VAP caused by any of the following pathogens:
  • Methicillin-resistant Staphylococcus aureus (MRSA)
  • Vancomycin-intermediate Staphylococcus aureus (VISA)
  • Pseudomonas aeruginosa
  • Vancomycin-resistant Enterococcus (VRE)
  • Acinetobacter baumanii
  • Stenotrophomonas maltophilia
  • Carbapenem-resistant Enterobacteriaceae (CRE)

Arms & Interventions

4 Days of Antibiotics Group

Participants will receive 4 days of antibiotic therapy administered as per the standard of care for the treatment of early ventilator associated pneumonia (VAP).

Intervention: Standard of Care Antibiotic Therapy

7 Days of Antibiotics Group

Participants will receive 7 days of antibiotic therapy administered as per the standard of care for the treatment of early ventilator associated pneumonia (VAP).

Intervention: Standard of Care Antibiotic Therapy

Outcomes

Primary Outcomes

Antibiotic Free Days

Time Frame: Up to 30 days

The number of days where participant did not require the use of antibiotics

Number of Participants With Reoccurring VAP

Time Frame: Up to 21 days

VAP recurrence will be reported as the number of participants with VAP occurring following completion of initial therapy.

Secondary Outcomes

  • Hospital Length Of Stay(Up to 1 year)
  • In-hospital Mortality(Up to 1 year)
  • Number of Days of Antibiotic Exposure(Up to 30 days)
  • Amount of Antibiotic Exposure(Up to 30 days)
  • Clinical Improvement as Measured by the Change in Clinical Pulmonary Infection Score (CPIS) From the First Study Day to the Last(From baseline to the last study day, up to 30 days)
  • Number of Participants With VAP Relapse(Up to 30 days)
  • Ventilator-free Days(Up to 30 days)
  • The Number of Participants With Empyema(Up to 30 days)
  • The Number of Participants That Received a Tracheostomy(Up to 30 days)
  • The Number of Participants With Non-pulmonary Infections(Up to 30 days)
  • ICU-free Days(Up to 30 days)

Study Sites (1)

Loading locations...

Similar Trials